Manja Jargosch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manja Jargosch has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Carsten B. Schmidt-Weber
Center of Allergy and Environment (ZAUM), Technical University Munich and Helmholtz Center Munich, German Research Center for Environmental Health
4 shared publications - Felix Lauffer
Department of Dermatology and Allergy, LMU Hospital, Munich, Germany
4 shared publications - Kilian Eyerich
Department of Dermatology and Venereology, Faculty of Medicine and Medical Center University Hospital Freiburg Freiburg Germany
4 shared publications - Tilo Biedermann
Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
4 shared publications - Christina Hillig
Department of Computational Health, Institute of Computational Biology , Helmholtz Munich, Neuherberg
3 shared publications - Jessica Eigemann
Department of Dermatology and Allergy, Technical University of Munich , Munich
3 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (3) , 461-472
Proliferation-associated protein 2G4 promotes keratinocyte proliferation and survival in psoriasis
Psoriasis is a non-communicable inflammatory skin disease that affects approximately 2%–3% of the world’s population. Given its high impact on quality of life and the fact that a subset of patients exhibits suboptimal or secondary loss of response to current treatments, identifying new therapeutic strategies is crucial. Proliferation-associated protein 2G4 (PA2G4) is a transcription factor that has been exclusively studied in cancer research, where it promotes cell growth and enhances tumourigenesis by inhibiting apoptosis. However, its role in inflammatory skin diseases remains largely unknown. This study focused on the pathophysiological and immunological functions of PA2G4 in psoriasis and evaluated its potential as a therapeutic target. Bulk, single-cell, and spatial RNA sequencing combined with immunohistochemistry were used to assess PA2G4 expression in psoriatic skin compared with that in non-lesional controls. Functional studies were performed in primary human keratinocytes and reconstructed human epidermis (RHE) models using the CRISPR/Cas9-mediated knockout (KO) of PA2G4 and pharmacological inhibition of PA2G4 with the small-molecule WS6. The regulatory effects of PA2G4 on cellular processes, such as proliferation, differentiation, and survival, were investigated using RNA-seq, western blot analysis, scratch assays, and annexin V staining. PA2G4 was highly abundant in psoriasis, and its expression was predominantly restricted to basal proliferating keratinocytes. Its gene expression is positively correlated with psoriasis severity, the degree of acanthosis, neutrophil infiltration, and genes which are upregulated in psoriasis. PA2G4 KO in primary human keratinocytes activated differentiation pathways while suppressing proliferation pathways, resulting in the downregulation of proliferation- and inflammation-related genes (e.g. MKI67, IL20, VEGFA, and HIF1A) and the upregulation of differentiation and cell adhesion markers (e.g. KRT6C, LCE2C, and DSG4). Functionally, the PA2G4 KO reduced keratinocyte proliferation in scratch assays, attenuated interleukin-22-induced acanthosis in RHE models, and promoted keratinocyte death. Pharmacological inhibition of PA2G4 using the small-molecule inhibitor WS6 similarly downregulated genes associated with proliferation and cell survival. PA2G4 could promote keratinocyte hyperproliferation and survival in psoriasis, thereby critically influencing epidermal homeostasis. Therefore, inhibition of PA2G4 may represent a new treatment option for psoriasis.
- 20 April 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (3) , 461-472
Open AccessProliferation-associated protein 2G4 promotes keratinocyte proliferation and survival in psoriasis
Psoriasis is a non-communicable inflammatory skin disease that affects approximately 2%–3% of the world’s population. Given its high impact on quality of life and the fact that a subset of patients exhibits suboptimal or secondary loss of response to current treatments, identifying new therapeutic strategies is crucial. Proliferation-associated protein 2G4 (PA2G4) is a transcription factor that has been exclusively studied in cancer research, where it promotes cell growth and enhances tumourigenesis by inhibiting apoptosis. However, its role in inflammatory skin diseases remains largely unknown. This study focused on the pathophysiological and immunological functions of PA2G4 in psoriasis and evaluated its potential as a therapeutic target. Bulk, single-cell, and spatial RNA sequencing combined with immunohistochemistry were used to assess PA2G4 expression in psoriatic skin compared with that in non-lesional controls. Functional studies were performed in primary human keratinocytes and reconstructed human epidermis (RHE) models using the CRISPR/Cas9-mediated knockout (KO) of PA2G4 and pharmacological inhibition of PA2G4 with the small-molecule WS6. The regulatory effects of PA2G4 on cellular processes, such as proliferation, differentiation, and survival, were investigated using RNA-seq, western blot analysis, scratch assays, and annexin V staining. PA2G4 was highly abundant in psoriasis, and its expression was predominantly restricted to basal proliferating keratinocytes. Its gene expression is positively correlated with psoriasis severity, the degree of acanthosis, neutrophil infiltration, and genes which are upregulated in psoriasis. PA2G4 KO in primary human keratinocytes activated differentiation pathways while suppressing proliferation pathways, resulting in the downregulation of proliferation- and inflammation-related genes (e.g. MKI67, IL20, VEGFA, and HIF1A) and the upregulation of differentiation and cell adhesion markers (e.g. KRT6C, LCE2C, and DSG4). Functionally, the PA2G4 KO reduced keratinocyte proliferation in scratch assays, attenuated interleukin-22-induced acanthosis in RHE models, and promoted keratinocyte death. Pharmacological inhibition of PA2G4 using the small-molecule inhibitor WS6 similarly downregulated genes associated with proliferation and cell survival. PA2G4 could promote keratinocyte hyperproliferation and survival in psoriasis, thereby critically influencing epidermal homeostasis. Therefore, inhibition of PA2G4 may represent a new treatment option for psoriasis.
- Open Access
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadx0637
Immunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis
Psoriasis (Pso) is a chronic inflammatory skin disease driven by T helper 17 (T H 17) cells, with several clinical subtypes. While self-reactive immune responses have been observed, the role of autoantigens in Pso remains unclear. Using immunopeptidomics, we identified serpin family B member 3 (SERPINB3) and SERPINB4 as candidate autoantigens in Pso skin. In a mouse model, the SERPINB3 ortholog Serpinb3b enhanced inflammation, promoted tissue-resident memory T cells, and skewed immunity toward a T H 2 phenotype. In humans, SERPINB3 reactivity was specifically associated with “eczematized psoriasis” (EczPso), a subtype marked by T H 2/T H 17 immune signatures. SERPINB3 protein was enriched in EczPso lesions and highly secreted by keratinocytes under combined T H 2/T H 17 stimulation. Lesional T cells from EczPso—but not from eczema or classical plaque Pso—proliferated in response to SERPINB3 and induced EczPso-like features in a skin model. Our findings identify SERPINB3 as an autoantigen driving a distinct Pso subtype, supporting more precise diagnosis and therapy.
- 24 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (43) , eadx0637
Open AccessImmunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis
Psoriasis (Pso) is a chronic inflammatory skin disease driven by T helper 17 (T H 17) cells, with several clinical subtypes. While self-reactive immune responses have been observed, the role of autoantigens in Pso remains unclear. Using immunopeptidomics, we identified serpin family B member 3 (SERPINB3) and SERPINB4 as candidate autoantigens in Pso skin. In a mouse model, the SERPINB3 ortholog Serpinb3b enhanced inflammation, promoted tissue-resident memory T cells, and skewed immunity toward a T H 2 phenotype. In humans, SERPINB3 reactivity was specifically associated with “eczematized psoriasis” (EczPso), a subtype marked by T H 2/T H 17 immune signatures. SERPINB3 protein was enriched in EczPso lesions and highly secreted by keratinocytes under combined T H 2/T H 17 stimulation. Lesional T cells from EczPso—but not from eczema or classical plaque Pso—proliferated in response to SERPINB3 and induced EczPso-like features in a skin model. Our findings identify SERPINB3 as an autoantigen driving a distinct Pso subtype, supporting more precise diagnosis and therapy.
- Open Access
- 8 August 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (6) , 1192-1203
Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus
Background: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease with various clinical subtypes. Although its pathogenesis is not yet fully understood, T-cell-mediated autoimmunity and elevated levels of type I interferons (IFNs) are two major factors that contribute to the development of cutaneous lesions. Type I IFNs transduce their signal via tyrosine kinase 2 (TYK2). Objectives: To investigate the impact of TYK2 signalling in preclinical models of CLE. Methods: CLE skin biopsies were investigated by RNA sequencing (RNAseq) and immunohistochemistry. T cells isolated from CLE skin biopsies (lesional T cells) were restimulated with anti-CD3/anti-CD28 and cytokine release was quantified by enzyme-linked immunosorbent assay and Luminex®. Primary human keratinocytes and three-dimensional skin models were stimulated with IFN-α or lesional T-cell supernatant in the presence or absence of the TYK2 inhibitor deucravacitinib, followed by RNAseq. Skin biopsies from patients with different CLE subtypes were treated ex vivo with deucravacitinib followed by real-time quantitative polymerase chain reaction. Results: Bulk RNAseq revealed a strong correlation between TYK2 and interface dermatitis, a histological hallmark of CLE. Immunohistochemistry confirmed a high abundance of TYK2 in different CLE subtypes. Inhibiting TYK2 reduced inflammation and normalized epidermal impairments in primary human keratinocytes, reconstructed human epidermis and CLE T cells. Ex vivo TYK2 inhibition in CLE skin biopsies reduced IFN response and necroptosis-related gene expression. Finally, four patients with different therapy-refractory subtypes of CLE (acute, subacute, chronic discoid, chilblain CLE) were successfully treated with deucravacitinib. Conclusions: IFN-α and T-cell-derived cytokines both contribute to skin inflammation in CLE. TYK2 inhibition is a promising approach for different subtypes of CLE as it controls inflammation in various preclinical models and patients with CLE who are refractory to treatment.
- 8 August 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (6) , 1192-1203
Open AccessTyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus
Background: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease with various clinical subtypes. Although its pathogenesis is not yet fully understood, T-cell-mediated autoimmunity and elevated levels of type I interferons (IFNs) are two major factors that contribute to the development of cutaneous lesions. Type I IFNs transduce their signal via tyrosine kinase 2 (TYK2). Objectives: To investigate the impact of TYK2 signalling in preclinical models of CLE. Methods: CLE skin biopsies were investigated by RNA sequencing (RNAseq) and immunohistochemistry. T cells isolated from CLE skin biopsies (lesional T cells) were restimulated with anti-CD3/anti-CD28 and cytokine release was quantified by enzyme-linked immunosorbent assay and Luminex®. Primary human keratinocytes and three-dimensional skin models were stimulated with IFN-α or lesional T-cell supernatant in the presence or absence of the TYK2 inhibitor deucravacitinib, followed by RNAseq. Skin biopsies from patients with different CLE subtypes were treated ex vivo with deucravacitinib followed by real-time quantitative polymerase chain reaction. Results: Bulk RNAseq revealed a strong correlation between TYK2 and interface dermatitis, a histological hallmark of CLE. Immunohistochemistry confirmed a high abundance of TYK2 in different CLE subtypes. Inhibiting TYK2 reduced inflammation and normalized epidermal impairments in primary human keratinocytes, reconstructed human epidermis and CLE T cells. Ex vivo TYK2 inhibition in CLE skin biopsies reduced IFN response and necroptosis-related gene expression. Finally, four patients with different therapy-refractory subtypes of CLE (acute, subacute, chronic discoid, chilblain CLE) were successfully treated with deucravacitinib. Conclusions: IFN-α and T-cell-derived cytokines both contribute to skin inflammation in CLE. TYK2 inhibition is a promising approach for different subtypes of CLE as it controls inflammation in various preclinical models and patients with CLE who are refractory to treatment.
- 27 April 2023
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 152 (2) , 408-419
The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response
- 27 April 2023
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 152 (2) , 408-419
The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response
- Open Access
- 6 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1461-1469.e5
Gene Expression–Based Molecular Test as Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin-Fixed and Paraffin-Embedded Tissue, Microbiopsies, and Tape Strips
- 6 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1461-1469.e5
Open AccessGene Expression–Based Molecular Test as Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin-Fixed and Paraffin-Embedded Tissue, Microbiopsies, and Tape Strips
- Open Access
- 1 September 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (39) , 26752-26761
Nuclear Factor of Activated T Cells Regulates the Expression of Interleukin-4 in Th2 Cells in an All-or-none Fashion
- 1 September 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (39) , 26752-26761
Open AccessNuclear Factor of Activated T Cells Regulates the Expression of Interleukin-4 in Th2 Cells in an All-or-none Fashion